AI
QNCX icon

ArchPoint Investors’s Quince Therapeutics QNCX Stock Holding History

ArchPoint Investors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15
Closed -$140K – 125
2020
Q1 		$140K Buy
15
+7
+88% +$69.1K 0.06% 93
2019
Q4 		$86K Buy
+8
New +$48.3K 0.03% 104

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

ArchPoint Investors's QNCX Position: Q2 2020 in Review

ArchPoint Investors sold out of Quince Therapeutics (QNCX) in Q2 2020, closing a stake of 15 shares — an estimated $140K sold.

ArchPoint Investors first reported a position in QNCX in Q4 2019 and held it in 2 quarters. The position peaked at $140K in Q1 2020. 81 funds tracked by Wall St. Rank hold QNCX as of Q2 2020.

  • ArchPoint Investors reported no remaining Quince Therapeutics position as of Q2 2020 after selling out during the quarter.
  • ArchPoint Investors sold 15 Quince Therapeutics shares in Q2 2020, an estimated $140K.
  • ArchPoint Investors first reported a position in Quince Therapeutics in Q4 2019 and held it in 2 quarters.
  • ArchPoint Investors's Quince Therapeutics position peaked at $140K in Q1 2020.
  • 81 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2020.

Based on ArchPoint Investors's 13F filing for Q2 2020, filed 31 Jul 2020.